Concepedia

Modified-release Formulation Modeling

Modified-Release Formulation Modeling is a computational or mathematical framework within oral dosing models that specifically characterizes the temporal dynamics of drug release and absorption for formulations designed to modulate the rate or location of drug delivery in the gastrointestinal tract.

24

Publications

886

Citations

134

Authors

40

Institutions

Publications per year

2017–2026

5

Parents

Publications

24

Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations

Álvaro Goyanes, Grace B. Hatton, Hamid A. Merchant et al. · International Journal of Pharmaceutics · 2015 · 94 citations · Full text

, , +17

In vitro–in vivo correlation (IVIVC) models for metformin after administration of modified‐release (MR) oral dosage forms to healthy human volunteers

Guhan Balan, Peter Timmins, Douglas S. Greene et al. · Journal of Pharmaceutical Sciences · 2001 · 89 citations

, , +17

Artificial Neural Networks in Evaluation and Optimization of Modified Release Solid Dosage Forms

Svetlana Ibrić, Jelena Djuriš, Jelena Parojčić et al. · Pharmaceutics · 2012 · 82 citations · Full text

, , +15

Novel Use of Similarity Factors<i>f</i><sub>2</sub>and<i>S</i><sub>d</sub>for the Development of Diltiazem HCl Modified-Release Tablets Using a 3<sup>2</sup>Factorial Design

Mukesh Gohel, Maulik Panchal · Drug Development and Industrial Pharmacy · 2002 · 71 citations

, , +17

Population PKPD modelling of the long‐term hypoglycaemic effect of gliclazide given as a once‐a‐day modified release (MR) formulation

Norbert Frey, Christian Laveille, Marie Paraire et al. · British Journal of Clinical Pharmacology · 2003 · 58 citations · Full text

, , +17

1–5 of 24

Authors

134

  1. ÁG
    Álvaro Goyanes

    University College London, United Kingdom

    3 publications · 170 citations

    3

    h-index

  2. AW
    Abdul W. Basit

    University College London, United Kingdom

    3 publications · 170 citations

    3

    h-index

  3. UG
    Ulf G. Eriksson

    AstraZeneca (Sweden), Sweden

    2 publications · 34 citations

    2

    h-index

  4. ES
    Erik Söderlind

    AstraZeneca (Sweden), Sweden

    2 publications · 34 citations

    2

    h-index

  5. MB
    Martin Bergstrand

    Uppsala University, Sweden

    2 publications · 34 citations

    2

    h-index

1–5 of 134

Institutions

40

  1. Bristol-Myers Squibb (United States)

    New York, United States

    3 h-index

    14 publications

    445 citations

  2. University College London

    London, United Kingdom

    3 h-index

    11 publications

    655 citations

  3. Universität Greifswald

    Greifswald, Germany

    2 h-index

    2 publications

    34 citations

  4. Pfizer (United States)

    New York, United States

    2 h-index

    33 publications

    839 citations

  5. AstraZeneca (Sweden)

    Södertälje, Sweden

    2 h-index

    4 publications

    68 citations

  6. Uppsala University

    Uppsala, Sweden

    2 h-index

    4 publications

    68 citations

  7. Bristol-Myers Squibb (United Kingdom)

    Moreton, United Kingdom

    2 h-index

    2 publications

    103 citations

  8. Research Triangle Park Foundation

    Durham, United States

    1 h-index

    1 publications

    12 citations

1–8 of 40

Venues

  1. Journal of Pharmaceutical Sciences

    3 publications · 157 citations

    3

    h-index

  2. Pharmaceutical Research

    3 publications · 46 citations

    3

    h-index

  3. International Journal of Pharmaceutics

    2 publications · 145 citations

    2

    h-index

  4. European Journal of Pharmaceutics and Biopharmaceutics

    EJPB · 2 publications · 78 citations

    2

    h-index

  5. Drug Development and Industrial Pharmacy

    2 publications · 102 citations

    2

    h-index

1–5